{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:01:21Z","timestamp":1787320881803,"version":"build-2736575974"},"reference-count":76,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/17425255.2025.2474126","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:39:04Z","timestamp":1740713944000},"page":"501-509","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[{"name":"University of Zurich","place":["Zurich, Switzerland"]},{"name":"Northwell Health","place":["Glen Oaks, USA"]},{"name":"Hofstra\/Northwell","place":["Hempstead, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[{"name":"Northwell Health","place":["Glen Oaks, USA"]},{"name":"Hofstra\/Northwell","place":["Hempstead, USA"]},{"name":"Center for Neuroscience","place":["Manhasset, USA"]},{"name":"Charit\u00e9 Universit\u00e4tsmedizin","place":["Berlin, Berlin, Germany"]},{"name":"partner site","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.195.52.s7"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.951544"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12435"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14544"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12546"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.17006"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12546"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2009.12.020"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab087"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21495"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.0640"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253241257062"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-023-00334-3"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20994"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2181073"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21121189"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15032su1"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00039-0"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab063"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab091"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00779-5"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1371014"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S326299"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02299-8"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-020-00127-y"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2021.11.030"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S332026"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S392351"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.09.014"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001148"},{"issue":"9","key":"e_1_3_5_33_1","first-page":"630","article-title":"Use of depot antipsychotics in Belgium between 1997 and 2016","volume":"63","author":"Tielens S","year":"2021","unstructured":"Tielens S, Destoop M, Morrens M. Use of depot antipsychotics in Belgium between 1997 and 2016. Tijdschr Psychiatr. 2021;63(9):630\u2013637.","journal-title":"Tijdschr Psychiatr"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2220962"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1549489"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab071"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-024-00900-9"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-024-00899-z"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001137"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m11308"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S197225"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw018"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyad067"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m14873"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m15095"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S41235"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-00996-8"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2024.2313550"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1397"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13207"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00745-1"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01102-2"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(23)00288-2"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1345623"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.832753"},{"key":"e_1_3_5_56_1","unstructured":"Shandong Luye Pharmaceutical Co. Ltd. Rykindo (risperidone) for extended-release injectable suspension for intramuscular use [prescribing information]. [cited2024 Jul 04]. Available from: https:\/\/www.luye.cn\/lvye_en\/rykindo.pdf"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000479"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13246"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2228686"},{"key":"e_1_3_5_60_1","unstructured":"Medincell. Teva and medincell announce positive phase 3 efficacy results from SOLARIS trial evaluating TEV-\u2018749 (olanzapine) as a once-monthly subcutaneous long-acting injectable in adults with schizophrenia. 2024 [cited 2024 Jul 4]. Available from: https:\/\/www.medincell.com\/wp-content\/uploads\/2024\/05\/PR_Solaris_08052024_EN_Final.pdf"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2022.2064308"},{"key":"e_1_3_5_62_1","unstructured":"Laboratorios Farmac\u00e9uticos Rovi SA. Okedi: EPAR - Product information Madrid Spain2023. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/okedi"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.11.009"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000139"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01089-w"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-116492"},{"key":"e_1_3_5_67_1","first-page":"S57","article-title":"A clinical trial to evaluate the pharmacokinetics, safety and tolerability of single doses of risperidone with the novel long-acting injectable technology ISM in healthy subjects","volume":"261","author":"Farr\u00e9 M","year":"2011","unstructured":"Farr\u00e9 M, Martinez-Gonzalez J, Cordero P, et al. A clinical trial to evaluate the pharmacokinetics, safety and tolerability of single doses of risperidone with the novel long-acting injectable technology ISM in healthy subjects. Eur Arch Psychiatry Clin Neurosci. 2011;261:S57.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000203"},{"key":"e_1_3_5_69_1","unstructured":"Laboratorios Farmac\u00e9uticos Rovi SA. Study to evaluate the efficacy and safety of risperidone ISM\u00ae in patients with acute schizophrenia: open label extension (PRISMA-3_OLE). 2022 [cited 2024 Jul 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03870880"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1177\/20451253241280046"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16115"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00735-3"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009355156"},{"issue":"7","key":"e_1_3_5_74_1","first-page":"17","article-title":"Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents","volume":"9","author":"Sheehan JJ","year":"2012","unstructured":"Sheehan JJ, Reilly KR, Fu DJ, et al. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 2012;9(7\u20138):17\u201323.","journal-title":"Innov Clin Neurosci"},{"key":"e_1_3_5_75_1","unstructured":"Laboratorios Farmac\u00e9uticos Rovi SA. RISVAN\u00ae (risperidone) for extended-release injectable suspension for intramuscular use Madrid Spain2024 [cited2024 May 07]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/214835s000lbl.pdf"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6152"},{"key":"e_1_3_5_77_1","unstructured":"Laboratorios Farmac\u00e9uticos Rovi SA. ROVI forecasts potential risperidone ISM\u00ae sales of between 200 and 300 million euros globally in upcoming years. 2024 [cited 2024 Jul 7]. Available from: https:\/\/www.rovi.es\/en\/content\/rovi-forecasts-potential-risperidone-ismr-sales-between-200-and-300-million-euros-globally"},{"key":"e_1_3_5_78_1","unstructured":"Laboratorios Farmac\u00e9uticos Rovi SA. Non-interventional study of risperidone ISM\u00ae in schizophrenia patients hospitalised due to a relapse (RESHAPE). 2023 [cited 2024 Jul 7]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05480046"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2025.2474126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:25:09Z","timestamp":1746170709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2025.2474126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/17425255.2025.2474126"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2025.2474126","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}